hotspot -WSS

hotspot

author：comprehensive 2025-10-01 18:23:33 - browse：4978

A yellow number 3 with an eye is surrounded by smaller, black number 3s on a pink background — 3 to watch coverage from STAT — Christine Kao/STAT

Health tech hopefuls might once have been used to a wealth of job options, especially in the pandemic’s early stages when investors pumped record-breaking dollar amounts into an unprecedented number of ventures.

That glut of opportunities meant workers could bargain harder for better job offers, demanding perks and flexibilities like permanent remote work or expensive fertility benefits. But belt-tightening and market consolidation across health tech companies have tipped the scales back in favor of employers, who are continuing to hire — for a seemingly dwindling number of positions.

It might feel like a downturn, although it’s possible that the industry is simply easing back into its pre-pandemic normal, before the massive infusion of venture dollars and the hype surrounding virtual care, said Brookings Institution research fellow Niam Yaraghi, who studies health care employment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： STAT Summit: Ending the crisis of Black deaths in the U.S.

WSS

Readout LOUD podcast: Live from the 2023 STAT Summit

3 trends to watch in health tech's hiring outlook for 2024

Is there really a nursing shortage in the U.S.?

The biotech scorecard for Q1: 17 stock

The biotech scorecard for Q1: 17 stock

STAT Summit: Meghan O’Rourke on making chronic illness visible

hotspot

hotspot

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

3 medical device trends to watch in 2024

Affirmative action in medical school literally saved lives

A single drug, study failures leave Anavex with nothing but cash

Affirmative action in medical school literally saved lives

ADCs take center stage as promising cancer treatments

BioMarin wins approval for gene therapy to treat hemophilia A

The biotech scorecard for Q1: 17 stock

How to save PrEP access — and even expand it

Smaller biotechs seek to piggyback on weight loss drug boom

leisure time

Study on Amgen’s bispecific immunotherapy produces positive data

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

White House finalizes ITC's import ban of latest Apple Watches

Cassava Sciences’ Alzheimer’s clinical trials should be halted

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

UCB departs biotech trade group BIO

focus

leisure time

Wikipedia

Wikipedia